Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Merus N.V. is a Dutch oncology company specializing in developing innovative multispecific antibody therapeutics using proprietary platforms like Biclonics®, Triclonics®, and ADClonics®. Its pipeline includes antibody candidates targeting solid tumors, including NRG1 fusion cancers, with FDA-approved therapies and ongoing clinical trials. The company collaborates globally to advance cancer treatments that harness immune mechanisms and target multiple tumor pathways.
This description was generated via AI from an annual report. Updated about 1 year ago.